Studies in breast and liver cancer showed a link between TP53 mutant tumors and increased cholesterol biosynthesis (Freed-Pastor et al, 2012; Moon et al, 2018), likely explaining this signature’s dominance in our TP53 mutant cohort. The gene discussed is TP53; the disease is liver cancer.